News
(2)April 2026
Caris Life Sciences CEO Halbert Receives $20.4 Million Compensation
# 🧾 What This Document Is This is a **DEF 14A, or Proxy Statement**, for Caris Life Sciences. You can think of it as a detailed invitation and information packet for the company's upcoming annual shareholder meeting. Its main job is to give shareholders the info they need to vote on important compa
CAI Annual Report Tracks Progress in Building Precision Medicine Platform
# 🧾 What This Document Is This is Caris Life Sciences' **Annual Report to Shareholders (ARS)**. Think of it as the company's comprehensive "year in review" document, sent directly to investors. It combines the formal 10-K financial report with a more visual, strategic overview of the business. You
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.